Thomas Mike, Turner Steve, Leather Dave, Price David
Department of General Practice and Primary Care, University of Aberdeen, Foresterhill Health Centre, Westburn Road, Aberdeen AB25 2AY.
Br J Gen Pract. 2006 Oct;56(531):788-90.
Inhaled corticosteroids are effective and safe treatments for childhood asthma in standard doses, yet at high dosages they may be associated with adverse events and suboptimal outcomes; add-on therapy is, therefore, recommended to minimise their use. We quantified prescribing of high-dose inhaled corticosteroids and add-on therapy in children in July 2003 and found that high-dose inhaled corticosteroids were prescribed to 10% of children aged 5-11 years and 6% of under-5's who were treated for asthma. Add-on therapy was lacking for almost half of these individuals. Some children were receiving treatment not in accord with current licences and evidence-based recommendations and, as such, may be at risk of adverse outcomes.
吸入性糖皮质激素以标准剂量用于儿童哮喘治疗时有效且安全,但高剂量使用时可能会出现不良事件且效果欠佳;因此,建议采用附加疗法以尽量减少其使用。我们对2003年7月儿童高剂量吸入性糖皮质激素的处方情况及附加疗法进行了量化,发现接受哮喘治疗的5至11岁儿童中有10%、5岁以下儿童中有6%使用了高剂量吸入性糖皮质激素。近一半使用高剂量吸入性糖皮质激素的儿童未接受附加疗法。一些儿童接受的治疗不符合当前的许可规定和循证医学建议,因此可能面临不良后果的风险。